Linden Adds Operating Partner

Linden Capital Partners has added Joseph Bernardo to its team as a new Operating Partner.

Mr. Bernardo has significant M&A experience and has been involved with over 25 due diligences, acquisitions, and integrations since the start of his career. He most recently served as the President of the Next-Generation Sequencing and Oncology division at Thermo Fisher Scientific. Mr. Bernardo has been with Thermo Fisher since 2008 and in addition to his work with next-generation technologies he was the president of the company’s ImmunoDiagnostics, Anatomic Pathology, and Fisher Healthcare divisions. Prior to joining Thermo Fisher, he served as the Senior Vice President of the Central Lab Business Unit at Siemens Healthcare. Mr. Bernardo holds a BS in Chemistry from Lafayette College and a MA in Chemistry from the University of Virginia. He is currently a Senior Advisor to The Boston Consulting Group.

“After spending my career with Thermo Fisher, Siemens, and Abbott, I am excited to partner with a healthcare exclusive private equity firm that respects and values my management, operational, R&D, and M&A experience in the diagnostics industry,” said Mr. Bernardo.

Mr. Bernardo will serve as the Chairman of SeraCare and will also act as the lead Operating Partner for Linden’s investments in future diagnostics and life sciences companies. Linden acquired SeraCare, a maker of diagnostic controls, reagents and molecular biomarkers used in a variety of in vitro diagnostics, in April 2012.

“Joe has a plethora of relevant experience and brings an unparalleled knowledge base in the diagnostics arena,” said Brian Miller, a Managing Partner at Linden. “We are thrilled for him to join SeraCare as Chairman and continue to build upon Linden’s expertise in diagnostics.”

Linden Capital Partners is focused exclusively on leveraged buyouts in the healthcare and life science industries with a specific interest in medical products, specialty distribution, pharmaceutical, and services segments of healthcare. Linden’s strategy is based upon three elements: healthcare and life science industry specialization; integrated financial and operating expertise; and strategic relationships with large corporations. The firm is based in Chicago (www.lindenllc.com).

© 2018 Private Equity Professional | January 3, 2018

Print Friendly, PDF & Email

Related Articles

Go Froth and Prosper? Middle market deal valuations continued to show signs of plateauing in the third quarter of 2018, according to GF Data’s just-released November report...
Littlejohn Closes Fund VI Littlejohn & Co. has held a final closing of Littlejohn Fund VI LP with $2.84 billion of committed capital, exceeding the fund’s target of $2.5 bi...
KPS Names New Partners KPS Capital Partners has promoted Raquel Palmer to Co-Managing Partner, and Ryan Baker and Kyle Mumford have been promoted to Partner. KPS Capital ...
Crossplane Launched in Dallas Crossplane Capital, a new lower-middle market private equity firm, has been launched in Dallas. The new firm was founded by partners Brian Hegi and Be...
Roark Closes New Funds Roark Capital Group has completed fundraising for its two newest funds, Roark Capital Partners V LP and Roark Capital Partners II Sidecar LP, with a t...
Peloton Formed by Ex-OTPP Pros Two former managers of Ontario Teachers’ Pension Plan have launched Peloton Capital Management to invest in mid-market buyouts in Canada and the US. ...